Department of Internal Medicine, University of Genova; and Cardiology Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.
Department of Cardiology (CBF), Charité University Medicine, Berlin, Germany; AND Division of Cardiology and Metabolism - Heart Failure, Cachexia & Sarcopenia; Department of Internal Medicine & Cardiology; and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), at Charité University Medicine, Berlin, Germany.
Eur J Heart Fail. 2018 May;20(5):879-887. doi: 10.1002/ejhf.1165. Epub 2018 Feb 21.
Cancer and heart failure (HF) are common medical conditions with a steadily rising prevalence in industrialized countries, particularly in the elderly, and they both potentially carry a poor prognosis. A new diagnosis of malignancy in subjects with pre-existing HF is not infrequent, and challenges HF specialists as well as oncologists with complex questions relating to both HF and cancer management. An increased incidence of cancer in patients with established HF has also been suggested. This review paper summarizes the epidemiology and the prognostic implications of cancer occurrence in HF, the impact of pre-existing HF on cancer treatment decisions and the impact of cancer on HF therapeutic options, while providing some practical suggestions regarding patient care and highlighting gaps in knowledge.
癌症和心力衰竭（HF）是常见的医疗状况，在工业化国家中的发病率稳步上升，尤其是在老年人中，并且两者都可能预后不良。在患有预先存在的 HF 的患者中，新诊断出恶性肿瘤并不罕见，这给 HF 专家和肿瘤学家带来了与 HF 和癌症管理相关的复杂问题。也有人提出，在已确诊 HF 的患者中，癌症的发病率增加。本文综述了 HF 中癌症发生的流行病学和预后意义、预先存在的 HF 对癌症治疗决策的影响以及癌症对 HF 治疗选择的影响，同时就患者护理提供了一些实用建议，并强调了知识空白。
